t-butyldicarbonate | 55130-19-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: t-butyldicarbonate
• 英文别名: Tert-butyl propan-2-yloxycarbonyl carbonate
• CAS: 55130-19-3
• 化学式: C₉H₁₆O₅
• 分子量: 204.223
• InChiKey: DMFIIOIXDFMXBL-UHFFFAOYSA-N

物化性质

• 沸点：
  241.1±9.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyldicarbonate 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 85.0h， 生成 7-(4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  Design, Synthesis and Antibacterial Evaluation of Novel Fluoroquinolone and its Derivatives

  摘要：

  设计并合成了加替沙星异构体[1-环丙基-6-氟-1,4-二氢-8-甲氧基-7-(2-甲基-1-哌嗪基)-4-氧代-3-喹啉羧酸]及其一系列衍生物，并对其体外抗菌活性进行了评估。初步结果表明，受试化合物 GI1、GI2、GI3 和 GI4 对表皮葡萄球菌具有很好的活性。此外，化合物 GI1、GI3 和 GI4 对肺炎克雷伯菌的 MIC 值为 0.015 μg/mL。值得注意的是，化合物 GI2 对所有测试污渍都表现出了最突出的活性。基于这些有希望的结果，一些测试化合物可被选为潜在的候选药物进行进一步评估。

  DOI：

  10.14233/ajchem.2014.15572
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 异丙醇 在 4-二甲氨基吡啶 作用下， 以 乙腈 为溶剂， 生成 碳酸二异丙酯 、 二碳酸双（1-甲基乙基）酯 、 t-butyldicarbonate 、 1,1-dimethylethyl 1-methylethyl carbonate
  参考文献：
  名称：

  Di-tert-butyl Dicarbonate and 4-(Dimethylamino)pyridine Revisited. Their Reactions with Amines and Alcohols¹

  摘要：

  The reaction of BOC2O in the presence and absence of DMAP was examined with some amines, alcohols, diols, amino alcohols, and aminothiols. Often, unusual products were observed depending on the ratio of reagents, reaction time, polarity of solvent, pK(a) of alcohols, or type of amine (primary or secondary). In reactions of aliphatic alcohols with BOC2O/DMAP, we isolated for the first time carbonic-carbonic anhydride intermediates; this helps explain the formation of symmetrical carbonates in addition to the O-BOC products. In the case of secondary amines, we succeeded to isolate unstable carbamic-carbonic anhydride intermediates that in the presence of DMAP led to the final N-BOC product. The effect of N-methylimidazole in place of DMAP was also examined.

  DOI：

  10.1021/jo000257f

文献信息

• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3901152A1

  公开（公告）日：2021-10-27

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, Y1 to Y4 and R1 to R6 are as described herein.

  这项发明提供了具有一般式(I)的新杂环化合物 其中A、B、L、Y1至Y4和R1至R6如本文所述。
• [EN] INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE<br/>[FR] INHIBITEURS DE FACTEUR XA ET AUTRES SERINE PROTEASES INTERVENANT DANS LA CASCADE DE COAGULATION
  申请人：WARNER LAMBERT CO

  公开号：WO2004024679A1

  公开（公告）日：2004-03-25

  This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

  该发明揭示了显示对丝氨酸蛋白酶Xa具有抑制作用的氨基酸衍生物。该发明还揭示了该化合物的药用盐、包含该化合物或其盐的药用组合物、制备该化合物的方法，以及将其用作治疗或预防哺乳动物异常血栓形成疾病状态的治疗剂的方法。
• [EN] NEW MOLECULES FOR ISOLATION OF POLYRIBOSOMES, RIBOSOMES, USES AND KITS THEREOF<br/>[FR] NOUVELLES MOLÉCULES POUR L'ISOLATION DE POLYRIBOSOMES, RIBOSOMES, UTILISATIONS ET KITS ASSOCIÉS
  申请人：IMMAGINA BIOTECHNOLOGY S R L

  公开号：WO2017013547A1

  公开（公告）日：2017-01-26

  Molecules of general Formula (I): able to bind to native polyribosomes engaged in active protein synthesis. The disclosure relates also to the use of the molecules of general Formula (I) for isolating at least one active ribosome from a biological sample, and for ribosome profiling, as well as kits for isolating at least one active ribosome from a biological sample.

  通用式（I）的分子能够结合到参与活跃蛋白质合成的原生多核体上。该公开还涉及使用通用式（I）的分子从生物样本中分离至少一个活跃核糖体，并用于核糖体剖析，以及用于从生物样本中分离至少一个活跃核糖体的工具包。
• Synthesis of 4-vinyl substituted β-lactams of the oxamazin family
  作者：Giuseppe Guanti、Eva Baldaro、Luca Banfi、Alberto Guaragna、Enrica Narisano、Umberto Valcavi

  DOI：10.1016/s0040-4020(01)85998-6

  日期：1988.1

  of the synthesis are: the preparation of protected α-amino-β-hydroxyacid 6 through ester enolate condensation of ethyl glycinate STABASE adduct 8 with CH-protected propiolaldehyde 9, the coupling of this acid with an appropriate protected hydroxylamine, the cyclization of resulting hydroxamate, and finally the acylation of the amino-group in 3 with ATMO side chain.

  已经制备了4-乙烯基取代的恶唑嗪15,16和3。合成的关键步骤是：通过甘氨酸乙酯STABASE加合物8与CH保护的丙醛9的酯烯醇缩合制备受保护的α-氨基-β-羟基酸6 ，将该酸与适当的受保护的羟胺偶联，环化生成异羟肟酸酯，最后将3中的氨基与ATMO侧链酰化。